Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Integrum AB

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Integrum AB

Regulatory records
5
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 5 FDA records to the applicant name Integrum AB. 4 entries are PMA supplements. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Aug 14, 2025 to Apr 15, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code PJY appears in 5 of the 5 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P190009, with 5 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: Krokslatts Fabriker 50, Mölndal, SE-431 37. Recorded on P190009/S011, decision dated Apr 15, 2026.

Changes described in PMA records

P190009/S011: OPRA Implant System

FDA’s recorded scope: approval for the following changes: i) changes to the transport packaging box dimensions and configuration, ii) minor changes to the package design of the fixture components; and iii) removal of the repacking step after sterilization

Apr 15, 2026 · Real-Time Process

P190009/S010: OPRA Implant System

FDA’s recorded scope: approval for revisions to the device labeling that was updated to include information on the Post-Approval Study (PAS), TFAOS PAS, for the OPRA Implant System

Mar 12, 2026 · Normal 180 Day Track No User Fee

P190009/S012: OPRA Implant System

FDA’s recorded scope: the replacement of the current laser machine used to create the BioHelix surface with a comparable machine in the manufacturing process.

Feb 12, 2026 · 30-Day Notice

P190009/S006: OPRA Implant System, Abutment component

FDA’s recorded scope: approval of an addition of a Low Plasticity Burnishing (LPB) step in the manufacturing process of the Abutment component of the OPRA device.

Nov 20, 2025 · 135 Review Track For 30-Day Notice

P190009/S009: OPRA Implant System

FDA’s recorded scope: Approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P190009

Aug 14, 2025 · Normal 180 Day Track No User Fee

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Integrum ABPMA supplementApr 15, 2026FDA
Integrum ABPMA supplementMar 12, 2026FDA
Integrum ABPMA supplementFeb 12, 2026FDA
Integrum ABPMA supplementNov 20, 2025FDA
Integrum ABPMA supplementAug 14, 2025FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 20, 2026.